Table 2 Treatment-emergent adverse events by grade and frequency (N = 44).

From: Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma

Adverse events

Grade

1

2

3

4

ALT elevated

12%

9%

  

Anaemia

 

14%

5%

 

Anorexia

26%

7%

  

AST elevated

19%

   

Back pain

 

5%

  

Cardiac troponin increased

  

2%

 

Chest pain

  

2%

 

Constipation

14%

9%

  

Cough

16%

   

Creatinine elevated

 

7%

  

Dehydration

  

2%

 

Diarrhoea

23%

12%

2%

 

Dizziness

  

2%

 

Dysgeusia

12%

   

Dyspnoea

  

2%

 

Erythema

  

2%

 

Fatigue

33%

19%

9%

 

Headache

12%

   

Hypertriglyceridaemia

12%

7%

  

Hypokalaemia

 

21%

9%

2%

Hypophosphataemia

  

5%

 

Insomnia

 

5%

  

Myocardial infarction

  

2%

 

Nausea

21%

7%

  

Neutropenia

 

9%

14%

5%

Pruritus

12%

   

Rash

30%

 

19%

 

Sinusitis

14%

   

Sore throat

12%

   

Thrombocytopenia

 

7%

5%

 
  1. Frequency of treatment-emergent adverse event regardless of causality graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.
Back to article page